

**Pediatric cortical vein thrombosis: Frequency and association with venous infarction**

Zak Ritchey, MS<sup>1</sup>; Amanda L. Hollatz, MA<sup>1</sup>; David Weitzenkamp, PhD<sup>2</sup>; Laura Z. Fenton, MD<sup>3</sup>; Emily C. Maxwell, PhD<sup>4</sup>; Timothy J. Bernard, MD<sup>1,4</sup>; Nicholas V. Stence, MD<sup>3</sup>

<sup>1</sup>Hemophilia and Thrombosis Center, University of Colorado Denver, Aurora, CO, USA

<sup>2</sup>Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, USA

<sup>3</sup>Department of Radiology, Children's Hospital Colorado, Aurora, CO, USA

<sup>4</sup>Departments of Pediatrics and Pediatric Neurology, Children's Hospital Colorado, Aurora, CO, USA

Corresponding author: Nicholas V. Stence, Department of Radiology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA; [nicholas.stence@childrenscolorado.org](mailto:nicholas.stence@childrenscolorado.org); Phone: 720-777-8509; Fax: 720-777-7264

Supplemental tables: 5

Supplemental Table I

**CVT Group: Clinical Outcomes and Clot Evolution**

<b>Age at Dx, y/Sex</b>	<b>Specific Location of Acute CVT</b>	<b>Site of Coexistent Thrombosis</b>	<b>Degree of Occlusion</b>	<b>Neurologic Status at Initial Follow-up Visit*</b>	<b>Subacute Recanalization</b>	<b>Chronic Recanalization</b>
6/F	L/R SCV	SSS	Complete	Persistent seizure, gait deficit	Complete	Not available
15/M	L Trolard V; R Labbé V	SSS; R TS, SigS, IJV	Complete	No deficit	Not available	Partial
2/M	L/R Trolard V, SCV	SSS; L SigS, IJV	Complete	Not available	Not available	Not available
17/F	R Labbé V; L/R SCV	SSS; R TS, SigS, IJV	Complete	Persistent HA	Complete	Not available
10/M	R Trolard V; L/R SCV	SSS; R TS, SigS, IJV	Complete	No deficit	Near complete	Complete
16/F	L/R Trolard V	SSS; R TS	Complete	Persistent HA	Near complete	Near complete
13/M	L/R Trolard V, SCV	SSS; R TS, SigS, IJV	Complete	Vision deficit, paresthesia	Near complete	Not available
16/F	L/R Trolard V, SCV	SSS	Complete	Persistent HA	Near complete	Not available
1/M	L/R Trolard V, SCV	SSS; L TS, SigS, IJV	Complete	Gait deficit	Near complete	Not available
17/F	L/R Trolard V, SCV	SSS; R TS, SigS, IJV	Complete	Persistent HA	Near complete	Not available
16/M	L Labbé V	None (isolated CVT)	Complete	Gait deficit	Complete	Complete
0/F	L/R Labbé V	None (isolated CVT)	Complete	Hypertonicity	Not available	Not available

CSVT=cerebral sinovenous thrombosis, CVT=cortical vein thrombosis, Dx=diagnosis, HA=headache, IJV=internal jugular vein, L=left, L/R=bilateral, R=right, SCV=multiple superior cerebral veins, SigS=sigmoid sinus, SSS=superior sagittal sinus, TS=transverse sinus; V=vein  
 \*Initial follow-up visit with a pediatric neurologist during the subacute period (6 weeks - 6 months)

**Supplemental Table II****Non-CVT Group: Clinical Outcomes and Clot Evolution**

<b>Age at Dx, y/Sex</b>	<b>Specific Location of Acute CSVT (non-CVT)</b>	<b>Degree of Occlusion</b>	<b>Neurologic Status at Initial Follow-up Visit*</b>	<b>Subacute Recanalization</b>	<b>Chronic Recanalization</b>
0/M	L TS	Partial	Vision deficit, hemineglect	Not available	Not available
14/M	SSS; R TS, SigS, IJV	Complete	HA, paresthesia, vision deficit	Partial	Near complete
15/F	SSS	Partial	Not available	Not available	Complete
16/F	L TS, SigS, IJV	Complete	No deficit	Near complete	Not available
8/M	R TS, SigS, IJV	Partial	Persistent HA, vision deficit	Not available	Not available
3/F	L TS, SigS, IJV	Partial	No deficit	Near complete	Not available
3/M	R TS, SigS, IJV	Complete	Persistent vision deficit	No Change	Not available
12/M	L TS; L/R SigS, IJV; CavS	Partial	No deficit	Partial	Not available
17/M	L SigS, IJV; L/R TS	Complete	No deficit	Partial	Not available
0/M	SSS	Partial	No deficit	Not available	Not available
17/M	L TS, SigS, IJV; CavS	Complete	HA, residual arm numbness	Partial	Not available
12/F	R SigS, IJV	Complete	Persistent HA	Complete	Not available
13/M	L TS, SigS, IJV	Complete	No deficit	Partial	Near complete
10/M	R TS, SigS, IJV	Complete	Residual abducens palsy, paresthesia	Partial	Complete
8/M	SSS; R TS, SigS, IJV	Complete	No deficit	Near complete	Not available
15/F	SSS; R TS, SigS, IJV	Complete	Persistent HA	Complete	Not available
6/F	R TS, SigS	Complete	No deficit	Near complete	Not available
3/F	R TS, SigS, IJV	Partial	Abducens palsy	Near complete	Not available
9/M	L TS, SigS, IJV	Complete	No deficit	Near complete	Complete
5/M	L SigS; R IJV; L/R TS	Complete	No deficit	Near complete	Complete
7/M	R TS, SigS, IJV	Partial	No deficit	Partial	Not available
0/M	SSS; L SigS; L/R TS	Complete	No deficit	Near complete	Complete
1/M	L TS, SigS	Complete	No deficit	Complete	Not available
12/M	SSS; L SigS, IJV	Partial	Aflexia and hemiparesis	Near complete	Not available
0/F	L/R TS	Complete	No deficit	Complete	Complete
13/F	L TS, SigS, IJV	Complete	Persistent HA	Near complete	Not available

SUPPLEMENTAL MATERIAL

0/F	R TS, SigS	Complete	No deficit	Near complete	Not available
0/M	SSS; R TS, SigS	Partial	Hypotonicity	Near complete	Not available
15/F	R TS, SigS, IJV	Complete	Not available	Near complete	Recurrence
10/M	R TS, SigS, IJV	Partial	Not available	Not available	Not available
0/M	R TS	Partial	Vision deficit, hemiparesis	Complete	Not available
3/M	R TS, SigS, IJV	Partial	No deficit	Complete	Not available
10/M	SSS	Partial	No deficit	Complete	Not available
9/M	R TS, SigS	Partial	No deficit	Near complete	Complete
3/F	L SigS, IJV	Partial	Persistent hemiparesis	Complete	Not available
9/M	R SigS, IJV	Complete	No deficit	Near complete	Not available
0/M	SSS; R TS, SigS	Complete	Hypertonicity	Partial	Partial
13/M	SSS; T TS, SigS, IJV	Partial	HA, new-onset seizure	Near complete	Not available

CSVT=cerebral sinovenous thrombosis, CVT=cortical vein thrombosis, Dx=diagnosis, HA=headache, IJV=internal jugular vein, L=left, L/R=bilateral, R=right, SigS=sigmoid sinus, SSS=superior sagittal sinus, TS=transverse sinus

\*Initial follow-up visit with a pediatric neurologist during the subacute period (6 weeks - 6 months)

**Supplemental Table III**

<b>Clinical Characteristics</b>	All (n=50)	CVT (n=12)	Non-CVT (n=38)	<i>P</i> value
Median age at CSVT, y (range)	9 (0-17)	14 (0-17)	8.5 (0-17)	0.1693
Sex, n (%)				
Male	32 (64)	6 (50)	26 (68)	0.3088
Race, n (%)				0.4169
Asian	0 (0)	0 (0)	0 (0)	
Black or African American	2 (4)	1 (8)	1 (2)	
Native American	0 (0)	0 (0)	0 (0)	
Pacific Islander	0 (0)	0 (0)	0 (0)	
White	42 (84)	11 (91)	31 (81)	
More than one race	1 (2)	0 (0)	1 (3)	
Unknown or not reported	5 (10)	0 (0)	5 (13)	
Ethnicity, n (%)				1.0000
Hispanic	10 (20)	2 (16)	8 (21)	
Not Hispanic	38 (76)	10 (83)	28 (73)	
Unknown	2 (4)	0 (0)	2 (5)	
Presenting signs/symptoms, n (%)				
Altered mental status/encephalopathy	15 (30)	7 (58)	8 (21)	0.0271
Focal neurological deficit	17 (34)	5 (41)	12 (31)	1.0000
Headache	32 (64)	9 (75)	23 (60)	0.4973
Papilledema	10 (20)	1 (8)	9 (23)	0.4155
Seizure	15 (30)	7 (58)	8 (21)	0.0271

**Supplemental Table IV**

<b>Presumed Risk Factors</b>	All (n=50)	CVT (n=12)	Non-CVT (n=38)	<i>P</i> value
Presumed risk factors, n (%)				
Chronic medical condition*	14 (28)	4 (33)	10 (26)	1.0000
Dehydration	9 (18)	3 (25)	6 (15)	1.0000
Encephalitis	2 (4)	0 (0)	2 (5)	1.0000
Family history of clotting disorder	7 (14)	4 (33)	3 (7)	0.0477
Mastoiditis	9 (18)	1 (8)	8 (21)	0.4251
Meningitis	4 (8)	0 (0)	4 (10)	0.5604
Otitis media	13 (26)	1 (8)	12 (31)	0.1466
Sinusitis	15 (30)	1 (8)	14 (36)	0.0787
Trauma	7 (14)	2 (16)	5 (13)	1.0000

\*Chronic medical conditions were assessed in all patients, and included headache disorder (10%, 5/50), hearing loss (6%, 3/50), obesity (4%, 2/50), type II diabetes mellitus (2%, 1/50), down syndrome (2%, 1/50), and turner syndrome (2%, 1/50).

Supplemental Table V

<b>Treatment at diagnosis and discharge</b>				
	All (n=50)	CVT (n=12)	Non-CVT (n=38)	<i>P</i> value
Treatment at diagnosis, n (%)				0.346
UFH	28 (56)	8 (67)	20 (53)	
LMWH	14 (28)	2 (17)	12 (32)	
Warfarin	2 (4)	0 (0)	2 (5)	
tPA with subsequent UFH	2 (4)	1 (8)	1 (3)	
ASA	1 (2)	1 (2)	0 (0)	
No treatment	7 (14)	1 (8)	6 (16)	
Treatment at discharge, n (%)				0.421
UFH	0 (0)	0 (0)	0 (0)	
LMWH	36 (72)	9 (75)	27 (71)	
Warfarin	12 (24)	4 (33)	8 (21)	
ASA	1 (2)	1 (2)	0 (0)	
No treatment	7 (14)	1 (8)	6 (16)	

ASA=Aspirin, LMWH=Low-molecular-weight heparin, tPA=Tissue plasminogen activator, UFH=Unfractionated heparin